BTIG analyst Marie Thibault raised the firm’s price target on Edwards Lifesciences (EW) to $103 from $100 and keeps a Buy rating on the shares. The are plenty of catalysts in 2026, with potential NCD, guideline updates, and launches fueling outyears acceleration, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences: Strategic Initiatives and Promising Developments Drive Raised Price Target
- Edwards Lifesciences: A Strong Growth Opportunity in Medtech with Expanding Market Potential and Robust Product Portfolio
- Edwards Lifesciences backs FY25 EPS view $2.56-$2.62, consensus $2.59
- Edwards Lifesciences sees FY26 adjusted EPS $2.80-$2.95, consensus $2.86
- Promising Outlook for Edwards Lifesciences: TAVR Expansion and Strong Growth Prospects Drive Buy Rating